1. CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. Issue 7 (23rd July 2021) Authors: Naing, Aung; Thistlethwaite, Fiona; De Vries, Elisabeth G.E.; Eskens, Ferry A.L.M.; Uboha, Nataliya; Ott, Patrick A.; LoRusso, Patricia; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A.; Randhawa, Manreet; Durm, Greg; Gil-Martin, Marta; Stroh, Mark; Hannah, Alison L.; A... Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience. Issue 22 (1st August 2022) Authors: Maron, Steven B.; Moya, Stephanie; Morano, Federica; Emmett, Matthew J.; Chou, Joanne F.; Sabwa, Shalom; Walch, Henry; Peterson, Bryan; Schrock, Alexa B.; Zhang, Liangliang; Janjigian, Yelena Y.; Chalasani, Sree; Ku, Geoffrey Y.; Disel, Umut; Enzinger, Peter; Uboha, Nataliya; Kato, Shumei; Yoshin... Journal: Journal of clinical oncology Issue: Volume 40:Issue 22(2022) Page Start: 2458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. TAS-102: a novel antimetabolite for the 21st century. (January 2016) Authors: Uboha, Nataliya; Hochster, Howard S Journal: Future oncology Issue: Volume 12:Number 2(2016) Page Start: 153 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗